Report Details the Impact of Covid-19 on Global Celiac Disease Drug Market

Celiac.com 10/08/2020 - InForGrowth has released its latest research report on the current market for celiac disease drugs, along with development trends and forecasts through 2026. The 2020 Celiac Disease Drug Market Report's analyses include: the macroeconomic factors influencing the growth of the Celiac Disease Drug market; key trends shaping market growth; regions growth opportunities; strategies of key market players.

The report seeks to assess the size of the current and future celiac disease drug market by analyzing historical data and future projections. It offers an overviews of market segments, including product types, applications, companies, and regions. 

Celiac.com Sponsor (A12):
Moreover, the report includes a timely analysis on the impact of the COVID-19 pandemic on the Celiac Disease Drug market.  Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. 

The COVID-19 pandemic will significantly affect the Celiac Disease Drug market in 2020 and beyond. The report assesses the impact of COVID-19 on the global economy, and on celiac drug markets, by analyzing: the impact of Covid-19 on global celiac drug production and demand; potential disturbances in the supply chain and market; and potential financial harm to firms and financial markets.

Also included in the report are detailed analyses of each segment of the celiac disease drug market, based on product type, application, region, and major market players, including F. Hoffmann-La Roche, Johnson & Johnson, Merck, Pfizer, ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer, Biogen, BioLineRx, Biotest, Bristol-Myers Squibb, Celgene, Takeda Pharmaceutical, Novartis, LFB Group, and Kedrion Biopharma.

Source: CORONA Virus/COVID19 impact here.